cylex® stimulated atp (Cylex Inc)
90
Structured Review
Cylex Inc
cylex® stimulated atp
Cylex® Stimulated Atp, supplied by Cylex Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cylex%C2%AE+stimulated+atp/cylex++stimulated+atp/pmc03758507-84-77-83
Average 90 stars, based on 1 article reviews
Cylex® Stimulated Atp, supplied by Cylex Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cylex%C2%AE+stimulated+atp/cylex++stimulated+atp/pmc03758507-84-77-83
Average 90 stars, based on 1 article reviews
cylex® stimulated atp - by Bioz Stars,
2026-10
90/100 stars
Images
1) Product Images from "A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes"
Article Title: A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes
Journal: Journal of Neurovirology
doi: 10.1007/s13365-013-0173-y
Figure Legend Snippet: Explorations of potential predictors of clinical deterioration at week 16 as measured by change in KPSI to week 16
Techniques Used: Clinical Proteomics
Related Articles
Clinical Proteomics:Article Title: A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes Article Snippet: The following variables of interest were tested for their potential correlation or association to KPSI change from baseline to week 16; except where specified, both baseline and change from baseline at week 4 results were tested: KPSI score (<50 vs ≥50, baseline only), EDSS score (<6.0 vs ≥6.0, baseline only), log 10 JCV DNA load in CSF, log 10 JCV DNA load in plasma, log 10 JCV DNA load in urine, CD3 + /CD4 + FACS count, FACS:Article Title: A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes Article Snippet: The following variables of interest were tested for their potential correlation or association to KPSI change from baseline to week 16; except where specified, both baseline and change from baseline at week 4 results were tested: KPSI score (<50 vs ≥50, baseline only), EDSS score (<6.0 vs ≥6.0, baseline only), log 10 JCV DNA load in CSF, log 10 JCV DNA load in plasma, log 10 JCV DNA load in urine, CD3 + /CD4 + FACS count, Polymerase Chain Reaction:Article Title: A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes Article Snippet: The following variables of interest were tested for their potential correlation or association to KPSI change from baseline to week 16; except where specified, both baseline and change from baseline at week 4 results were tested: KPSI score (<50 vs ≥50, baseline only), EDSS score (<6.0 vs ≥6.0, baseline only), log 10 JCV DNA load in CSF, log 10 JCV DNA load in plasma, log 10 JCV DNA load in urine, CD3 + /CD4 + FACS count, Fluorescence:Article Title: A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes Article Snippet: The following variables of interest were tested for their potential correlation or association to KPSI change from baseline to week 16; except where specified, both baseline and change from baseline at week 4 results were tested: KPSI score (<50 vs ≥50, baseline only), EDSS score (<6.0 vs ≥6.0, baseline only), log 10 JCV DNA load in CSF, log 10 JCV DNA load in plasma, log 10 JCV DNA load in urine, CD3 + /CD4 + FACS count, |